TaiRx

TaiRx Enterprise Value

The Enterprise Value (EV) of TaiRx (6580.TWO) as of Oct 18, 2026 is 2.26 B TWD. In the previous year, Enterprise Value (EV) was 1.76 B TWD — a change of 28.59% (higher).

Enterprise Value

2.26 BTWD

YoY

28.59%

Last updated:

Enterprise Value (EV) of TaiRx is 2025 2.26 B TWD. Enterprise Value (EV) of TaiRx was 2024 1.76 B TWD. It decreases by 28.59% higher compared to the previous year.

The TaiRx Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
1.74 B TWD
Jan 1, 2019
1.95 B TWD
Jan 1, 2020
1.60 B TWD
Jan 1, 2021
1.72 B TWD
Jan 1, 2022
1.92 B TWD
Jan 1, 2023
1.62 B TWD
Jan 1, 2024
1.76 B TWD
Jan 1, 2025
2.26 B TWD
The TaiRx Enterprise Value history
YEAREnterprise ValueYoY
2.26 BTWD+28.59%
1.76 BTWD+8.93%
1.62 BTWD-15.87%
1.92 BTWD+11.58%
1.72 BTWD+7.91%
1.60 BTWD-18.04%
1.95 BTWD+12.20%
1.74 BTWD+4.52%
1.66 BTWD+8.24%
1.53 BTWD-6.45%
1.64 BTWD+9.24%
1.50 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx Inc, listed on the Taiwan Stock Exchange under ticker 6580.TWO with ISIN TW0006580004, is a biotechnology company based in Taipei City, Taiwan. The company operates within the Health Care sector, focusing on research and development of novel drug products for cancer treatment. TaiRx went public through an IPO on June 20, 2017. Its primary focus includes the development of cancer treatment drugs and sepsis adjuvant therapy drugs. The company's product portfolio includes CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, and TRX-105. Among these, CVM-1118 and Rexis are currently in clinical trials. Zelnite is distributed to domestic medical institutions at all levels through distributors. TaiRx maintains a corporate website at https://www.trx.com.tw/, where further information about its operations and products can be found. The company is engaged in the research and development of innovative pharmaceutical solutions, targeting significant unmet medical needs in oncology and sepsis treatment. TaiRx's activities are centered on advancing drug candidates through clinical development and commercialization within the Taiwanese market and potentially beyond. The company's operations are conducted from its headquarters in Taipei City, reflecting its commitment to contributing to the healthcare industry in Taiwan and globally. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

Enterprise Value (EV) of TaiRx is 2.26 B TWD in 2025.

Enterprise Value (EV) of TaiRx changed from 1.76 B TWD to 2.26 B TWD, representing a 28.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) TaiRx since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s TWD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' TWD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s TaiRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TaiRx

All Key Metrics — TaiRx